MassBio Releases 2018 Industry Snapshot

Published on: 

Pharmaceutical Executive

The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, in partnership with EvaluatePharma, which shows Massachusetts biotechs accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016.

The report shows that 2018 has already surpassed 2017 in terms of total Massachusetts IPOs at 15, which accounts for nearly 40% of all US-based biotech IPOs (January – July 2018).

Job growth in the Massachusetts biopharma industry remains strong, with consistent 4-5% increases in the last few years, and nearly 30% growth over the last decade (28% from 2008 – 2017). Massachusetts also continues to attract a greater share of public funding, with:


  • Five of the top 6 NIH-funded independent hospitals

  • 57% of all NIH funding to Independent Hospitals

  • $1.25 billion to Massachusetts centers of Higher Education and Research Institutes in 2017

To download the full report, visit here.